Yes, protein markers can guide treatment decisions by identifying specific characteristics of the cancer. For example, patients with HER2-positive breast cancer may benefit from targeted therapies like trastuzumab. Similarly, BRAF mutations in melanoma can be targeted with specific inhibitors.
